Tissue factor pathway inhibitor overexpression inhibits hypoxia-induced pulmonary hypertension

American Journal of Respiratory Cell and Molecular Biology

Volumn 43, Issue 1, 2010, Pages 35-45

  White, Thomas A ^a   Witt, Tyra A ^a   Pan, Shuchong ^a   Mueske, Cheryl S ^a   Kleppe, Laurel S ^a   Holroyd, Eric W ^a   Champion, Hunter C ^b,c   Simari, Robert D ^a  

^a MAYO CLINIC   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Hypoxia; Pulmonary hypertension; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

CYCLINE; TISSUE FACTOR PATHWAY INHIBITOR; TRANSGELIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HEMODYNAMICS; HYPOXIA; LUNG ARTERY PRESSURE; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PULMONARY HYPERTENSION;

ANIMALS; ANOXIA; CELL PROLIFERATION; GENE EXPRESSION REGULATION; HEMODYNAMICS; HYPERTENSION, PULMONARY; LIPOPROTEINS; LUNG; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUSCLE, SMOOTH, VASCULAR; PROLIFERATING CELL NUCLEAR ANTIGEN; THROMBOPLASTIN;

MURINAE; MUS;

EID: 78349234248     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2009-0144OC     Document Type: Article

References (53)

1. Girgis RE, Mathai SC. Pulmonary hypertension associated with chronic respiratory disease. Clin Chest Med 2007;28:219-232.
2. Simonneau G, Galie N, Rubin LJ, Langleben D, SeegerW, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(Suppl S)5S-12S.
3. Cooper R, Ghali J, Simmons BE, Castaner A. Elevated pulmonary artery pressure: an independent predictor of mortality. Chest 1991;99:112-120. (see comment).
4. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981;36:752-758. (Pubitemid 12249743)
5. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003;21:892-905.
6. Incalzi RA, Fuso L, De Rosa M, Di Napoli A, Basso S, Pagliari G, Pistelli R. Electrocardiographic signs of chronic cor pulmonale: a negative prognostic finding in chronic obstructive pulmonary disease. Circulation 1999;99:1600-1605. (see comment).
7. Voelkel NF, Cool CD. Pulmonary vascular involvement in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003;46:28s-32s.
8. Presberg KW, Dincer HE. Pathophysiology of pulmonary hypertension due to lung disease. Curr Opin Pulm Med 2003;9:131-138.
9. Stenmark KR, Mecham RP. Cellular and molecular mechanisms of pulmonary vascular remodeling. Annu Rev Physiol 1997;59:89-144.
10. Howell K, Ooi H, Preston R, McLoughlin P. Structural basis of hypoxic pulmonary hypertension: the modifying effect of chronic hypercapnia. Exp Physiol 2004;89:66-72.
11. Hayashida K, Fujita J,Miyake Y, Kawada H, Ando K, Ogawa S, Fukuda K. Bone marrow-derived cells contribute to pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension. Chest 2005;127:1793-1798.
12. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006;99:675-691.
13. Pak O, Aldashev A, Welsh D, Peacock A. The effects of hypoxia on the cells of the pulmonary vasculature. Eur Respir J 2007;30:364-372.
14. Wagenvoort CA. Classifying pulmonary vascular disease. Chest 1973;64:503-504.
15. Cirillo P, Cali G, Golino P, Calabro P, Forte L, De Rosa S, Pacileo M, Ragni M, Scopacasa F, Nitsch L, et al. Tissue factor binding of activated factor vii triggers smooth muscle cell proliferation via extracellular signal-regulated kinase activation. Circulation 2004;109:2911-2916.
16. Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Sumiyoshi A. Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb Haemost 1996;75:389-392.
17. Broze GJ Jr. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 1992;29:159-169.
18. Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995;46:103-112.
19. Broze GJ Jr. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis 1995;6:S7-S13.
20. Girard TJ, Broze GJ Jr. Tissue factor pathway inhibitor. Methods Enzymol 1993;222:195-209.
21. Kamikubo Y, Nakahara Y, Takemoto S, Hamuro T, Miyamoto S, Funatsu A. Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Lett 1997;407:116-120.
22. Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Kamikubo Y, Sumiyoshi A. Tissue factor pathway inhibitor inhibits aortic smooth muscle cell migration induced by tissue factor/factor viia complex. Thromb Haemost 1997;78:1138-1141.
23. Hembrough TA, Ruiz JF, Papathanassiu AE, Green SJ, Strickland DK. Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor. J Biol Chem 2001;276:12241-12248.
24. Herve P, Humbert M, Sitbon O, Parent F, Nunes H, Legal C, Garcia G, Simonneau G. Pathobiology of pulmonary hypertension: the role of platelets and thrombosis. Clin Chest Med 2001;22:451-458.
25. Dartevelle P, Fadel E, Mussot S, Chapelier A, Herve P, de Perrot M, Cerrina J, Ladurie FL, Lehouerou D, Humbert M, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004;23:637-648.
26. Altman R, Scazziota A, Rouvier J, Gurfinkel E, Favaloro R, Perrone S, Fareed J. Coagulation and fibrinolytic parameters in patients with pulmonary hypertension. Clin Cardiol 1996;19:549-554.
27. Bakouboula B, Morel O, Faure A, Zobairi F, Jesel L, Trinh A, Zupan M, Canuet M, Grunebaum L, Brunette A, et al. Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;177:536-543. (Pubitemid 351442193)
28. White RJ, Meoli DF, Swarthout RF, Kallop DY, Galaria II, Harvey JL, Miller CM, Blaxall BC, Hall CM, Pierce RA, et al. Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007;293:L583-L590.
29. White RJ, Galaria II, Harvey J, Blaxall BC, Cool CD, Taubman MB. Tissue factor is induced in a rodent model of severe pulmonary hypertension characterized by neointimal lesions typical of human disease. Chest 2005;128(Suppl):612S-613S. (Pubitemid 43054157)
30. Campian ME, Hardziyenka M, Michel MC, Tan HL. How valid are animal models to evaluate treatments for pulmonary hypertension? Naunyn Schmiedebergs Arch Pharmacol 2006;373:391-400.
31. Yan SF, Zou YS, Gao Y, Zhai C, Mackman N, Lee SL, Milbrandt J, Pinsky D, Kisiel W, Stern D. Tissue factor transcription driven by egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci USA 1998;95:8298-8303. (Pubitemid 28326107)
32. Yan SF, Mackman N, Kisiel W, Stern DM, Pinsky DJ. Hypoxia/ hypoxemia-induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. Arterioscler Thromb Vasc Biol 1999;19:2029-2035. (Pubitemid 29422232)
33. Yan SF, Pinsky DJ, Stern DM. A pathway leading to hypoxia-induced vascular fibrin deposition. Semin Thromb Hemost 2000;26:479-483.
34. Lawson CA, Yan SD, Yan SF, Liao H, Zhou YS, Sobel J, Kisiel W, Stern DM, Pinsky DJ. Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. J Clin Invest 1997;99:1729-1738. (Pubitemid 27163825)
35. Pan S, Kleppe LS, Witt TA, Mueske CS, Simari RD. The effect of vascular smooth muscle cell-targeted expression of tissue factor pathway inhibitor in a murine model of arterial thrombosis. Thromb Haemost 2004;92:495-502. (Pubitemid 39248006)
36. Champion HC, Bivalacqua TJ, Toyoda K, Heistad DD, Hyman AL, Kadowitz PJ. In vivo gene transfer of prepro-calcitonin generelated peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse. Circulation 2000;101:923-930. (see comment).
37. Paddenberg R, Stieger P, von Lilien AL, Faulhammer P, Goldenberg A, Tillmanns HH, Kummer W, Braun-Dullaeus RC. Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice. Respir Res 2007;8:15.
38. West J, Fagan K, Steudel W, Fouty B, Lane K, Harral J, Hoedt-Miller M, Tada Y, Ozimek J, Tuder R, et al. Pulmonary hypertension in transgenic mice expressing a dominant-negative bmprii gene in smooth muscle. Circ Res 2004;94:1109-1114. (Pubitemid 38579706)
39. Hales CA, Kradin RL, Brandstetter RD, Zhu YJ. Impairment of hypoxic pulmonary artery remodeling by heparin in mice. Am Rev Respir Dis 1983;128:747-751.
40. Novotny WF, Brown SG, Miletich JP, Rader DJ, Broze GJ Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991;78:387-393.
41. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (epi). Thromb Res 1988;50:803-813.
42. Hassell KL. Altered hemostasis in pulmonary hypertension. Blood Coagul Fibrinolysis 1998;9:107-117.
43. Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc 1985;60:16-25.
44. Chaouat A, Weitzenblum E, Higenbottam T. The role of thrombosis in severe pulmonary hypertension. Eur Respir J 1996;9:356-363.
45. Wagenvoort CA, Mulder PG. Thrombotic lesions in primary plexogenic arteriopathy: similar pathogenesis or complication? Chest 1993;103:844-849. (see comment).
46. Mackman N. The role of the tissue factor-thrombin pathway in cardiac ischemia-reperfusion injury. Semin Vasc Med 2003;3:193-198.
47. Pawlinski R, Tencati M, Hampton CR, Shishido T, Bullard TA, Casey LM, Andrade-Gordon P, Kotzsch M, Spring D, Luther T, et al. Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation 2007;116:2298-2306. (see comment).
48. Pawlinski R, Tencati M, Holscher T, Pedersen B, Voet T, Tilley RE, Marynen P, Mackman N. Role of cardiac myocyte tissue factor in heart hemostasis. J Thromb Haemost 2007;5:1693-1700.
49. Nakamura Y, Nakamura K, Ohta K, Matsubara H, Yutani C, Hamuro T, Kato H, Ohe T. Anti-inflammatory effects of long-lasting locally-delivered human recombinant tissue factor pathway inhibitor after balloon angioplasty. Basic Res Cardiol 2002;97:198-205.
50. Singh R, Pan S, Mueske CS, Witt T, Kleppe LS, Peterson TE, Slobodova A, Chang JY, Caplice NM, Simari RD. Role for tissue factor pathway in murine model of vascular remodeling. Circ Res 2001;89:71-76.
51. Singh R, Pan S, Mueske CS, Witt TA, Kleppe LS, Peterson TE, Caplice NM, Simari RD. Tissue factor pathway inhibitor deficiency enhances neointimal proliferation and formation in a murine model of vascular remodelling. Thromb Haemost 2003;89:747-751.
52. Camerer E, Huang W, Coughlin SR. Tissue factor- and factor x-dependent activation of protease-activated receptor 2 by factor viia. Proc Natl Acad Sci USA 2000;97:5255-5260.
53. Ahamed J, Belting M, Ruf W. Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1. Blood 2005;105:2384-2391.